New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - 100 iu/ml - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride - treatment of diabetes mellitus.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - 100 iu/ml - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - insulin human, rdna - solution for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - insulin - parenteral liquid/solution/suspension - insulin hormone active 40.0 iu/ml - endocrine system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - insulin deficiency

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro 100 [iu] in 1 ml - humalog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell their physicians

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro 100 [iu] in 1 ml - humalog mix75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro injection, (rdna origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. humalog mix75/25 has a more rapid onset of glucose–lowering activity compared with humulin 70/30 while having a similar duration of action. this profile is achieved by combining the rapid onset of humalog with the intermediate action of insulin lispro protamine suspension. humalog mix75/25 is contraindicated during episodes of hypoglycemia and in patients sensitive to insulin lispro or any of the excipients contained in the formulation.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin human -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin human -